| Affymax receives $10M milestone payment from Takeda - Bizjournals.com |
|
|
Bizjournals.com The Palo Alto-based biopharmaceutical company Affymax (NASDAQ:AFFY) has developed an investigational drug called peginesatide, previously known as Hematide, to treat anemia in dialysis patients with chronic kidney disease. It received the milestone ... Affymax(R) Receives $10 Million Milestone Payment for FDA Filing of New Drug |